Publications
| Title | Abstract | Year(sorted ascending) Filter | PMID Filter |
|---|
| [in vitro effect of cefixime against 200 strains of branhamella catarrhalis. comparison with cefotaxime]. | the in vitro activity of cefixime was tested against 200 strains of branhamella catarrhalis. of these strains, 146 had been collected during 1987 from 15 different "centres hospitaliers généraux", through a multicenter collaborative investigation organized by the "collège de bactériologie-virologie-hygiène des hôpitaux généraux". the remaining 54 strains were isolated at the "centre hospitalier", of aix-en-provence. the strains originated from: bronchopulmonary collections: 80.2 per cent, sinusi ... | 1989 | 2530531 |
| rapid detection of bordetella pertussis by a monoclonal antibody-based colony blot assay. | monoclonal antibodies to bordetella pertussis filamentous hemagglutinin (fha) and lipopolysaccharide (lps) were used in a colony blot enzyme-linked immunosorbent assay designed for rapid detection of b. pertussis. bacterial colonies from bordet-gengou agar plates were blotted onto nitrocellulose filter disks, lysed by immersion in chloroform, and reacted with monoclonal antibodies. following reaction with peroxidase-conjugated rabbit anti-mouse immunoglobulin antisera and 4-chloro-1-naphthol, bl ... | 1989 | 2542357 |
| comparative analysis of the transferrin and lactoferrin binding proteins in the family neisseriaceae. | intact cells of several bacterial species were tested for their ability to bind human transferrin and lactoferrin by a solid-phase binding assay using horseradish peroxidase conjugated transferrin and lactoferrin. the ability to bind lactoferrin was detected in all isolates of neisseria and branhamella catarrhalis but not in isolates of escherichia coli or pseudomonas aeruginosa. transferrin-binding activity was similarly detected in most isolates of neisseria and branhamella but not in e. coli ... | 1989 | 2543489 |
| azithromycin (cp-62,993) in acute exacerbations of chronic bronchitis: an open clinical, microbiological and pharmacokinetic study. | a group of 21 patients admitted to hospital with acute purulent exacerbations of chronic bronchitis was treated for five days with a new oral macrolide azithromycin. they received one dose of 500 mg on the first day, followed by 250 mg once daily thereafter. pre-treatment sputum cultures were typical for this district, but the cultures during and after treatment showed many haemophilus influenzae infections persisting. geometric mean mics of azithromycin for these organisms rose from 1.23 mg/l ( ... | 1989 | 2547747 |
| [a minor epidemic of pertussis cough in brno]. | in the course of six months the authors investigated 32 children aged 1-32 months with pertussoid cough. this number included one child where pertussis was confirmed in a 25-month-old properly vaccinated child and parapertussis in an 8-month-old incompletely vaccinated infant. in the remaining children by cultivation or serological examination a different aetiology was found (rs virus, adenovirus, parainfluenza 2, m. pneumoniae, h. influenzae, branhamella catarrhalis). | 1989 | 2551513 |
| comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. | the in vitro activities of ticarcillin, piperacillin, clavulanic acid, tazobactam, ticarcillin-clavulanate, and piperacillin-tazobactam against 819 bacterial isolates were compared. the two beta-lactamase inhibitors, clavulanic acid and tazobactam, had little useful antibacterial activity but enhanced the activities of the penicillins against beta-lactamase-producing strains of haemophilus influenzae, branhamella catarrhalis, and methicillin-susceptible staphylococcus aureus; all strains were su ... | 1989 | 2552904 |
| studies to optimize the in vitro testing of piperacillin combined with tazobactam (ytr 830). | the combination of piperacillin and the beta-lactamase inhibitor tazobactam (formerly ytr 830) was studied to determine optimal disk concentrations and dilution testing conditions. in addition, the potency of the combination was compared to that of piperacillin alone. the spectrum of piperacillin was greatly expanded by the addition to tazobactam principally against beta-lactamase producing strains of haemophilus influenzae, escherichia coli, morganella morganii, proteus vulgaris, providencia st ... | 1989 | 2560422 |
| [bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field]. | bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil (cpdx-pr, cs-807), a new oral cephem antibiotic, were carried out in the field of pediatrics. the results obtained are summarized as follows. 1. antibacterial activities of r-3746 (na-salt of cefpodoxime (cpdx] against clinically isolated strains of streptococcus pneumoniae, streptococcus pyogenes, staphylococcus aureus, enterococcus faecalis, branhamella catarrhalis, escherichia coli, proteus mirabilis and haemophilus ... | 1989 | 2562789 |
| the surface of branhamella catarrhalis: a systematic approach to the surface antigens of an emerging pathogen. | the incidence of b. catarrhalis as a cause of otitis media is increasing. as strategies for preventing infections caused by streptococcus pneumoniae and nontypable h. influenzae are developed, the relative importance of b. catarrhalis will increase further in the next decade. a goal of studies of surface antigens is to identify potential vaccine components. surface antigens of b. catarrhalis include omps, los and fimbriae. preliminary studies indicate that omps and los are relatively antigenical ... | 1989 | 2564660 |
| nosocomial branhamella catarrhalis in a paediatric intensive care unit: risk factors for disease. | there have been few reports on branhamella catarrhalis as a nosocomial pathogen, and no risk factors for nosocomial infection have been identified. we report 11 cases (mean age 22 months) of nosocomial branhamella catarrhalis respiratory tract infection in a paediatric intensive care unit (picu) over a two-year period. there were 2 cases of pneumonia and 9 cases of bronchitis. branhamella catarrhalis was the sole isolate recovered in 6 cases and was associated with other respiratory pathogens in ... | 1989 | 2567760 |
| intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections. | seventy-one adult patients with 72 infections were treated, by random selection, with intravenous/oral ciprofloxacin or intravenously administered ceftazidime. twenty-seven additional patients with 29 infections who were not appropriate for random assignment were treated in an open study with intravenously administered ciprofloxacin only; the latter infections were generally more serious or were caused by ceftazidime-resistant organisms. the most common doses were ciprofloxacin, 200 mg intraveno ... | 1989 | 2589361 |
| should novobiocin be clinically re-evaluated? | the current novobiocin spectrum of antimicrobial activity was evaluated by testing 585 staphylococci (393 oxacillin-resistant) and 779 other bacterial strains. novobiocin inhibited 98.5% of all staphylococcal isolates (mic 90, 0.25 micrograms/ml) and a significant number of other gram-positive species at less than or equal to 1 microgram/ml. pathogenic neisseria, haemophilus influenzae, and branhamella catarrhalis were also very susceptible to novobiocin, e.g., mic 100, less than or equal to 1 m ... | 1989 | 2591171 |
| comparison of the nasal bacterial floras in two groups of healthy subjects and in patients with acute maxillary sinusitis. | the nasal bacterial flora was studied in 183 healthy men entering military service (entry group), 103 healthy recruits in service (service group), and 185 recruits with acute maxillary sinusitis. the 267 nasal and ipsilateral sinus aspirate findings in the same patients with acute maxillary sinusitis were compared pairwise. in the entry group presumed sinus pathogens were only rarely isolated from the nasal cavities: haemophilus influenzae in 4%, streptococcus pneumoniae in 1%, branhamella catar ... | 1989 | 2592539 |
| clinical efficacy of sulbactam/ampicillin in the treatment of moderately severe bacterial infections. | 20 patients with moderately severe bacterial infections were studied to determine the clinical efficacy and safety of parenteral sulbactam/ampicillin. there were 9 female and 11 male patients. their mean age was 51 years. 8 patients had pneumonia, 5 urinary tract infection, 4 cellulitis of the leg and 3 had pustular tonsillitis. 85% of patients had resolution of fever and symptoms within 48 hours of commencing treatment. 95% had successful treatment outcome. the organisms isolated included e. co ... | 1989 | 2609176 |
| [detection of chlamydia trachomatis antigen for diagnosis of respiratory infection i. cross reaction with bacteriae consisting normal flora respiratory tract]. | we examined the cross reaction of chlamydia trachomatis (c. trachomatis) by antigen detection method using eia against the aerobic bacteria which colonize in the respiratory tract of children. chlamydiazyme showed a cross reaction among 5 out of 7 species of gram negative bacteria (= 71.4%) and neisseria and branhamella catarrhalis showed a cross reaction even in low concentrations of 1 x 10(3-4) cfu/ml. there were no gram positive bacteria which showed cross reaction. ideia mark iii did not rea ... | 1989 | 2614091 |
| [therapy of chronic recurrent respiratory tract infections]. | in 1987, the most frequently identified pathogens in chronic respiratory tract infections in our clinic were haemophilus influenzae, pseudomonas aeruginosa, branhamella catarrhalis, streptococcus pneumoniae, staphylococcus aureus and klebsiella pneumoniae. recurrent infection is a common phenomenon in patients with chronic respiratory tract infections, including chronic bronchitis, chronic bronchiolitis and bronchiectasis. h. influenzae is the most common pathogen in such patients. macrolides, t ... | 1989 | 2615085 |
| [comparison of amoxicillin and amoxiclav in the therapy of respiratory infections]. | randomly hospitalized patients with respiratory tract infections admitted to three pulmonary departments of the golnik institute for pulmonary diseases and tuberculosis were enrolled in an open, comparative clinical study of amoksiklav and amoxicillin. a group of 26 patients with a mean age of 64.5 years presenting with pneumonia (13), exacerbation of chronic bronchitis (12) and bronchiectasis (1) were given amoskilav, while another 20 patients with a mean age of 61.4 years presenting with pneum ... | 1989 | 2636405 |
| bacterial tracheitis in children. | we examined the records of 14 patients aged 7 months to 10 1/4 years who were treated for bacterial tracheitis from may 1982 to december 1987; the management protocol for 13 of the patients included the use of nasotracheal intubation. the infection was caused by staphylococcus aureus in seven, haemophilus influenzae in three, branhamella catarrhalis in one and streptococcus pneumoniae in one. both h. influenzae and b. catarrhalis were isolated in another patient, and no organism was found in the ... | 1989 | 2642395 |
| direct and indirect pathogenicity of beta-lactamase-producing bacteria in mixed infections in children. | the recent emergence of numerous aerobic and anaerobic beta-lactamase-producing bacterial strains has been associated with an increase in the failure rate of penicillins in the therapy of infection caused by these organisms. these include respiratory tract, skin of soft tissue, female genital tract, intra-abdominal, and other miscellaneous infections. the important aerobic beta-lactamase-producing bacteria (blpb) include staphylococcus aureus, branhamella catarrhalis, haemophilus sp., neisseria ... | 1989 | 2644068 |
| roxithromycin. a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. | roxithromycin is an acid-stable orally administered antibacterial macrolide structurally related to erythromycin. it has an in vitro antibacterial profile similar to that of erythromycin, with activity against staphylococcus aureus, s. epidermidis, streptococcus pneumoniae, s. pyogenes, branhamella catarrhalis, mycoplasma pneumoniae, legionella pneumophila, chlamydia trachomatis, gardnerella vaginalis, haemophilus ducreyi, some anaerobes and other less common pathogens. roxithromycin has a pharm ... | 1989 | 2651088 |
| clinical efficacy and tolerance of bacampicillin and amoxycillin suspensions in children with acute otitis media. | a total of 97 children with acute otitis media were entered into a single-blind, parallel-group study to compare the efficacy and tolerance of suspensions of bacampicillin, given twice daily, with amoxycillin, given three times daily. the daily dosage was about 40 mg/kg body weight in each case and the duration of treatment was 10 days. patients were examined before the start of treatment, at an early follow-up visit within 2-3 weeks after the start of treatment and at a late follow-up visit 4-6 ... | 1989 | 2651176 |
| clinical overview of enoxacin. | enoxacin is a new fluoroquinolone that will be available as oral and intravenous preparations. this drug is bactericidal for a wide range of organisms, including staphylococcus aureus, s. epidermidis, enterobacteriaceae and pseudomonas aeruginosa. in addition, neisseria gonorrhoeae is exquisitely susceptible, as is branhamella catarrhalis. the evaluation of the clinical activity of enoxacin is still relatively new, but published studies reveal a good deal of potential in the treatment of infecti ... | 1989 | 2653698 |
| review of the in-vitro spectrum and characteristics of cefmetazole (cs-1170). | the in-vitro antimicrobial qualities of cefmetazole are summarized from a review of over 30 publications. cefmetazole, a 7 alpha-methoxy cephalosporin, is shown to have an antimicrobial spectrum closely resembling cefoxitin's. however, cefmetazole is approximately two- to eight-fold more active than cefoxitin against commonly isolated species such as escherichia coli, klebsiella spp., proteus mirabilis, staphylococcus aureus, pyogenic streptococci, pneumococci, and haemophilus influenzae. cefmet ... | 1989 | 2656622 |
| worldwide clinical experience with sultamicillin. | sultamicillin at an adult dose of 375-750 mg twice daily or a pediatric dose of 50 mg/kg/d provides effective outpatient/office therapy for community-acquired infections of the upper and lower respiratory tract, urinary tract, and skin/soft tissue structures. given the incidence of haemophilus influenzae and branhamella catarrhalis in otitis media and the frequent occurrence of beta-lactamase-producing strains, it is particularly appropriate for the therapy of otitis media in infants and childre ... | 1989 | 2660868 |
| [fluoroquinolones: pharmacology, antibacterial spectrum and indications in pneumology]. | fluoroquinolones are antibiotics that act principally on dna gyrase. at the moment, resistance to these antibiotics is purely chromosome-mediated. as regards pharmacokinetics, these compounds have a high bioavailability and penetrate extremely well into tissues and cells. therapeutic concentrations are obtained in bronchial mucosa and lung tissue. in severe lower respiratory tract infections fluoroquinolones must be given in combination with other antibiotics to prevent the emergence of resistan ... | 1989 | 2662344 |
| [clinical studies on sulbactam/ampicillin in the field of pediatrics]. | during 8 months from october 1986 to may 1987, the clinical efficacy of sulbactam/ampicillin (sbt/abpc) was evaluated in 63 pediatric inpatients with various infections. clinical efficacies were evaluable in 58 patients among them (consisting of 2 patients with sepsis, 3 with tonsillitis, 12 with bronchitis, 6 with bronchopneumonia, 24 with pneumonia, 1 with phlegmon, 2 with lymphadenitis, 1 with impetigo and 7 with urinary tract infection) and were excellent in 40 patients and good in 17 with a ... | 1989 | 2664249 |
| [clinical evaluation of sulbactam/ampicillin in children]. | sulbactam/ampicillin (sbt/abpc), a combination at a fixed ratio of abpc and sbt which is an irreversible inhibitor of beta-lactamase in a 2:1 ratio, was clinically evaluated for its efficacy and safety in 24 patients with ages from 5 month-old to 12 years old with bacterial infection. the results obtained are summarized as follows. 1. a pharmacokinetic study following 30 mg/kg sbt/abpc administration by 30 minutes drip infusion or intravenous bolus injection showed that mean half-lives of sbt an ... | 1989 | 2664251 |
| [susceptibilities of clinical isolates to antibacterial agents. a study mainly focused on ofloxacin (the second report). reported by the research group for testing ofloxacin susceptibility on clinical isolates]. | susceptibilities of various clinical isolates to ofloxacin (oflx) and other antibacterial drugs were examined at 128 hospital laboratories in 36 prefectures throughout japan between april, 1986 and march, 1987. the results were totalized with an emphasis mainly on oflx and were compared with data obtained in the previous year. in this study, identification and susceptibility tests of the isolates were carried out at each hospital laboratory and the tests were performed according to the 1-dilutio ... | 1989 | 2664255 |
| inoculum effect. | the inoculum effect (ie) is a laboratory phenomenon that is described as a significant increase in the minimal inhibitory concentration of an antibiotic when the number of organisms inoculated is increased. the ie generally occurs with beta-lactam antibiotics in relation to beta-lactamase-producing bacteria. an ie occurs with the first- and second-generation cephalosporins against staphylococcus aureus and less often with the quinolones, beta-lactam-resistant penicillins, cefoxitin, and aminogly ... | 1989 | 2664999 |
| laboratory survey of fluoroquinolone activity. | fluoroquinolones are active against a wide variety of bacteria. the antibacterial spectra of fluoroquinolones encompass staphylococci, bacillus species, and corynebacterium species implicated in infections of the immunocompromised host; enterobacteriaceae; most intestinal pathogens; and many gram-negative organisms commonly causing nosocomial infections. haemophilus influenzae, haemophilus ducreyi, neisseria gonorrhoeae, neisseria meningitidis, and branhamella catarrhalis are highly susceptible ... | 1989 | 2672262 |
| comparative in vitro activity of a new quinolone, am-1091. | the in vitro activity of a new quinolone, am-1091 [7-(3-amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro- 4-oxo- 3-quinoline carboxylic acid hydrochloride], was compared with those of ciprofloxacin, ofloxacin, beta-lactams, and gentamicin. am-1091 inhibited 90% of the isolates of the family enterobacteriaceae at less than or equal to 0.12 micrograms/ml. for many species am-1091 was 2-fold more active than ciprofloxacin and 2- to 32-fold more active than ofloxacin. it inhibited e ... | 1989 | 2675753 |
| test-retest reliability of the nasopharyngeal culture in children. | aspects of test-retest reliability of the nasopharyngeal culture were evaluated in children with otitis media and in ear, nose and throat (ent)-healthy children, in all 174 cases. the nasopharyngeal colonization of streptococcus pneumoniae, haemophilus influenzae, branhamella catarrhalis and beta-haemolytic streptococci was determined for a group of children with well-defined otitis media effusion (ome). the valitity of the results was then tested in a new group of children with ome. despite sea ... | 1989 | 2679807 |
| cefixime. a review of its antibacterial activity. pharmacokinetic properties and therapeutic potential. | cefixime, previously designated fk027, fr17027 and cl284635, is an orally active cephalosporin with a broad spectrum of antibacterial activity in vitro. it is particularly active against many enterobacteriaceae, haemophilus influenzae. streptococcus pyogenes, streptococcus pneumoniae and branhamella catarrhalis, and is resistant to hydrolysis by many beta-lactamases. cefixime has little activity against staphylococcus aureus and is inactive against pseudomonas aeruginosa. cefixime is distinguish ... | 1989 | 2684593 |
| nonculture detection of haemophilus influenzae in sputum with monoclonal antibodies specific for outer membrane lipoprotein p6. | isolation of haemophilus influenzae from sputum is hampered by overgrowth by other microorganisms or by antibiotic treatment of the patient. to overcome this problem in the detection of h. influenzae, an in situ immunoperoxidase staining technique was developed with monoclonal antibody (mab) 8bd9, immunoglobulin subclass g2a. mab 8bd9 appeared to be directed to an epitope on the outer membrane lipoprotein p6 of h. influenzae. the species specificity of mab 8bd9 was analyzed by staining isolates ... | 1989 | 2685026 |
| in vitro antimicrobial activity and susceptibility testing of ofloxacin. current status. | the fluoroquinolone, ofloxacin, exhibits a broad antibacterial spectrum. based on our data and a review of the literature, ofloxacin inhibited essentially 100 percent of staphylococci, including oxacillin-resistant strains, haemophilus influenzae, neisseria spp. and branhamella catarrhalis. ninety-five percent of enterobacteriaceae were susceptible to ofloxacin. pseudomonas aeruginosa and enterococci were less susceptible: 79 and 63 percent, respectively, were susceptible (minimal inhibitory con ... | 1989 | 2690614 |
| the concept of indirect pathogenicity by beta-lactamase production, especially in ear, nose and throat infection. | a recent increase in numbers of beta-lactamase-producing strains of aerobic and anaerobic gram-negative bacteria in upper respiratory tract infections has been associated with increased failure rates of penicillins in eradication of these infections. these organisms include staphylococcus aureus, haemophilus influenzae, branhamella catarrhalis and bacteroides spp. these infections include chronic otitis media, chronic sinusitis and mastoiditis, and chronic recurrent tonsillitis. the indirect pat ... | 1989 | 2691486 |
| cefmetazole (cs-1170), a "new" cephamycin with a decade of clinical experience. | in vitro and in vivo study results were reviewed from cefmetazole, a "new" parenteral cephamycin. cefmetazole's spectrum of activity was comparable to that of second-generation cephalosporins, which includes clinical coverage of many enterobacteriaceae, staphylococcus spp., streptococci, haemophilus spp., pathogenic neisseria, branhamella catarrhalis, and anaerobic bacteria. cefmetazole was generally more potent (two- to eightfold) than cefoxitin against organisms within their spectrums and was ... | 1989 | 2692950 |
| [susceptibility of bacteria isolated from patients with lower respiratory tract infections to antibiotics (1986)]. | enlisting the help of various research institutions across the nation, ikemoto et al. have been pooling cultures of clinical isolates of respiratory tract infections and mapping out the correlations between patient backgrounds and the causative bacteria and the changes in the sensitivity spectra of the bacteria to various antibacterial and antibiotic agents annually since 1981. the following is a report of the 1986 findings. during the period from september, 1986 to march, 1987, 558 cases of res ... | 1989 | 2695657 |
| the prevention of severe lower respiratory infections in chronic bronchitis. | chronic bronchitis remains as a serious medical problem for many adults and a smaller proportion of children in the united states. the frequency of severe lower respiratory infections in patients with chronic bronchitis is quite variable. the infectious agents most likely responsible for severe lower respiratory disease include pneumococci, nontypable haemophilus influenza, mycoplasma pneumoniae, and branhamella catarrhalis among the bacteria, and influenza a and b viruses, with parainfluenza an ... | 1989 | 2697051 |
| [pertussis syndrome: study of 74 cases]. | pertussis syndrome controversy induced us to study 74 hospitalized patients, with pertussis cough and bordetella sp isolation in 29, other bacteria in 24 and viruses in 21. the most frequently isolated bacteria in the patients with negative culture for bordetella were haemophilus influenzae, streptococcus pneumoniae and branhamella catarrhalis. the viruses with highest incidence were respiratory syncitial viruses. the negative culture for bordetella, the lack of antibiotherapy previous to obtent ... | 1989 | 2698068 |
| differentiation of some species of neisseriaceae and other bacterial groups by dna-dna hybridization. | dna-dna hybridization using total genomic dna probes may represent a way of differentiating between miscellaneous bacterial species. this was studied with type and reference strains of 20 species in moraxella, kingella, and other selected gram-negative groups. both radioactive and biotin labelling were employed. most of the species examined were easily distinguished, such as moraxella (branhamella) catarrhalis, m.(b.) ovis, m. atlantae, m. phenylpyruvica, m. osloensis, neisseria elongata, n. men ... | 1989 | 2730785 |
| comparative in vitro activity of ciprofloxacin and other unrelated antimicrobials against bacterial respiratory tract pathogens. | ciprofloxacin is a new fluorinated 4-quinolone with a broad spectrum of antimicrobial activity which includes both gram-negative and gram-positive bacteria. in this study the in vitro activity of ciprofloxacin has been determined against bacteria associated with respiratory tract infections and compared with that of other antimicrobial agents used in the therapy of such infections. ciprofloxacin (mic90 0.008 mg/l) was highly active against haemophilus influenzae, including isolates producing bet ... | 1989 | 2737080 |
| [antimicrobial activity of cefteram comparison with other oral antibiotics]. | antimicrobacterial activities of cefteram (cftm) against clinical isolates collected in 1988 were compared with those of new beta-lactams. 1. antibacterial activities of cftm against streptococcus pneumoniae, streptococcus pyogenes, haemophilus influenzae, branhamella catarrhalis isolated from acute respiratory tract infections were 8- to 16-fold higher than those of cefaclor (ccl). 2. activities of cefixime (cfix) were superior to those of cftm against b. catarrhalis, escherichia coli, klebsiel ... | 1989 | 2746861 |
| in vitro activities of a dual-action antibacterial agent, ro 23-9424, and comparative agents. | the in vitro activity of the dual-action antibacterial agent ro 23-9424 was compared with those of cefotaxime, ceftazidime, ciprofloxacin, fleroxacin, imipenem, and amikacin against 358 aerobes and anaerobes. the mic ranges, mics for 50 and 90% of the strains (mic50s and mic90s), and percentage of strains susceptible for each agent at the recommended susceptible mic breakpoint were determined for each genus. the mic90s (micrograms per milliliter) of the agents against members of the family enter ... | 1989 | 2782857 |
| in-vitro activity of fce 22101 against respiratory tract pathogens with reference to production of beta-lactamases. | fce 22101 is a new penem with broad antibacterial spectrum, excluding the pseudomonads, and has stability to many beta-lactamases. fce 22101 and imipenem were very potent against the bacteria studied, including beta-lactamase producing strains, which can be isolated from patients with respiratory tract infections (mic less than or equal to 8 mg/l). no strains were found to be resistant to fce 22101. fce 22101 was rapidly bactericidal and more stable to inactivation by beta-lactamases from branha ... | 1989 | 2786517 |
| in-vitro activity of a new penem fce 22101. | the in-vitro activity of a new penem fce 22101 was evaluated in comparison with other antimicrobial agents against 966 aerobic and anaerobic gram-negative and gram-positive bacteria. fce 22101 inhibited 90% of enterobacteriaceae, haemophilus influenzae, h. parainfluenzae, h. ducreyi, neisseria gonorrhoeae, branhamella catarrhalis, staphylococcus aureus, staph. epidermidis and group b streptococcus at concentrations of 0.12-4.0 mg/l. pseudomonas aeruginosa was resistant with mic90 of greater than ... | 1989 | 2786518 |
| the bacteriology of acute maxillary sinusitis. | sinus secretions obtained by antral aspiration from 347 patients with acute maxillary sinusitis were examined bacteriologically. special attention was paid to the method by which anaerobic bacteria could be recovered. on the total, 485 sinus secretion samples were examined, of these 336 were aspirates, 149 yields of injection-aspirations. aerobic bacteria were cultured from 263 aspirates and from 100 injection-aspiration samples. only anaerobes were recovered from 6 sinuses. bacterial culture wa ... | 1989 | 2786617 |
| empirical treatment without bronchoscopy for pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. | an empirical approach to treating pneumocystis carinii pneumonia was adopted in a prospective study of 73 men with antibodies to human immunodeficiency virus 1 (hiv-1) presenting with respiratory problems. at presentation 49 patients (group 1) were thought to have a history, findings at clinical examination, chest radiograph, and arterial blood gas tensions typical of pneumocystis pneumonia, and empirical treatment was begun immediately. twenty four patients (group 2) were thought to have featur ... | 1989 | 2788935 |
| lomefloxacin, a new fluoroquinolone. studies on in vitro antimicrobial spectrum, potency, and development of resistance. | lomefloxacin (ny-198; sc-47111), a potent new difluoroquinolone, was studied to compare its in vitro activity with that of other antimicrobials against 2194 clinical isolates. lomefloxacin showed excellent inhibitory and bactericidal activity against strains of enterobacteriaceae and inhibited greater than 99% of the isolates at a concentration of 4 micrograms/ml or less. lomefloxacin exhibited good-to-moderate activity against strains of acinetobacter (mic90 4 micrograms/ml) and pseudomonas aer ... | 1989 | 2791485 |
| [clinical and pharmacokinetic study on cefodizime, a new cephalosporin antibiotic, in the pediatric infections]. | cefodizime (thr-221, cdzm), a new cephalosporin antibiotic, was evaluated for its safety and efficacy in 27 children with various bacterial infections. the episodes of infections included pneumonia (6 cases), bronchopneumonia (11 cases), lung abscess (1 case), acute pharyngitis (2 cases), cervical lymphadenitis (1 case), infected cephalohematoma (1 case), urinary tract infection (1 case), sepsis (2 cases) and purulent meningitis (2 cases). cdzm was effective in all but one, and its efficacy rate ... | 1989 | 2795854 |
| ticarcillin/clavulanic acid combination. treatment of bacterial infections in hospitalized children. | eighteen patients 2 months to 11 years of age with culture proven bacterial infections were treated with parenteral ticarcillin/clavulanic acid in a noncomparative study. seven patients had pneumonia, two had tracheobronchitis, three had soft tissue abscess, two had periorbital cellulitis, three had urinary tract infection and one had purulent bursitis. four of the 18 were bacteremic. organisms treated included staphylococcus aureus (6), pseudomonas aeruginosa (5), haemophilus influenzae (2), br ... | 1989 | 2805557 |
| comparative in-vitro activity of meropenem on clinical isolates from the united kingdom. | mics of meropenem were determined for a wide range of common bacteria of clinical importance. for enterobacteriaceae, aeromonas spp., haemophilus influenzae, branhamella catarrhalis, neisseria gonorrhoeae, gardnerella vaginalis, campylobacter coli/jejuni, beta-haemolytic streptococci and anaerobes other than clostridium difficile, mics were almost always within the range 0.002-0.5 mg/l. the activity of meropenem for these organisms was always greater than that of imipenem and piperacillin, and w ... | 1989 | 2808214 |
| [pharmacokinetic, bacteriological and clinical studies on cefpodoxime proxetil in the field of pediatrics]. | pharmacokinetic, bacteriological and clinical studies on cefpodoxime proxetil (cpdx-pr, cs-807), a newly developed oral cephem, were carried out in the treatment of infectious diseases in the field of pediatrics. 1. since cpdx demonstrates very powerful antimicrobial actions against such gram-negative bacilli as escherichia coli, salmonella sp., klebsiella pneumoniae and serratia sp., such gram-positive cocci as streptococcus pyogenes and streptococcus pneumoniae, and beta-lactamase producing br ... | 1989 | 2810729 |
| [laboratory and clinical studies on cefteram pivoxil in the field of pediatrics]. | laboratory and clinical studies on cefteram pivoxil(cefteram) a new cephem antibiotic, were carried out in the field of pediatrics. the results obtained are summarized as follows: 1. serum concentrations, urinary concentrations and urinary recovery rates of cefteram (cftm) were determined upon oral administration after meal of cefteram pivoxil (cftm-pi) at doses of 3 mg/kg granules in 2 cases and 6 mg/kg granules in 2. peak serum levels of cftm were obtained at 3 hours in 2 cases and 4 hours in ... | 1989 | 2810748 |
| [clinical studies on cefteram pivoxil granules in pediatrics]. | a newly developed cephalosporin, cefteram pivoxil (cftm-pi, t-2588), was evaluated clinically in 40 patients. a pharmacokinetic study was also performed with 8 patients. cftm-pi was administered as granules. one patient was given cftm-pi at a dose of 1.5 mg/kg, each of 3 patients was given the drug at a dose of 3 mg/kg and each of 4 patients at a dose of 6 mg/kg. in most cases, serum concentrations of cftm were determined at 2, 3, 4, and 6 hours after dosing. urinary concentrations of cftm were ... | 1989 | 2810757 |
| antimicrobial activity of the new macrolide flurithromycin against haemophilus influenzae, streptococcus pneumoniae, streptococcus pyogenes, branhamella catarrhalis and staphylococcus aureus. | 1989 | 16312369 | |
| accumulation of trospectomycin by strains of salmonella typhimurium, escherichia coli and haemophilus influenzae. | trospectomycin, unlike aminoglycosidic aminocyclitols, is accumulated by a nonsaturable, energy-independent, diffusional process in salmonella typhimurium, escherichia coli and haemophilus influenzae. a deep rough mutant of s typhimurium was more susceptible and accumulated the drug faster, and f porin deficient mutants of e coli were more resistant than parental strains. trospectomycin likely uses both porin and nonporin pathways to cross the outer membrane. an e coli strain effectively accumul ... | 1990 | 22553440 |
| shunt-associated ventriculitis caused by branhamella catarrhalis. | 1990 | 1969445 | |
| pili (fimbriae) of branhamella species. | pili (fimbriae) have frequently been found to be involved in the attachment of bacteria to mucosal epithelial cells, an important initial step in the disease process. the purpose of this study was to determine if branhamella catarrhalis expresses type 4 pili. | 1990 | 1971156 |
| superoxol and aminopeptidase tests for identification of pathogenic neisseria species and moraxella (branhamella) catarrhalis. | the superoxol test, and prolyl aminopeptidase and gammaglutamyl aminopeptidase tests were evaluated for the detection of pathogenic neisseria spp. using 317 strains of neisseria-ceae. the superoxol test was positive for all 116 gonococci and 62 moraxella (branhamella) catarrhalis strains, but also for three strains of neisseria meningitidis, one strain of neisseria lactamica and eight saprophytic neisseriae. when using strains grown on thayer-martin medium, the positive and negative predictive v ... | 1990 | 1974848 |
| electron microscopic observation of branhamella catarrhalis. | the hemagglutination (ha) test was done on 85 strains of branhamella catarrhalis, isolated from sputum of patients with respiratory infections; 53% were ha positive strains. three ha positive and three ha negative strains were selected and were observed under the electron microscope. the bacterial cell wall appeared to be lobulated and its total thickness was about 38 nm. the nuclear region consisted of whorls or fibrils and dense bodies. five strains were fimbriated and one strain was nonfimbri ... | 1990 | 1983027 |
| receptors for human plasminogen on gram-negative bacteria. | a total of 188 strains representing 11 species of gram-negative bacteria were examined for the ability to interact with human plasminogen. highly purified human plasminogen was labeled with 125i, and its uptake by different bacterial strains was measured. all 14 strains of haemophilus influenzae and all 13 strains of branhamella catarrhalis tested were positive with respect to plasminogen uptake. also, eight species belonging to the family enterobacteriaceae were tested, and of those, proteus mi ... | 1990 | 1688419 |
| studies of the outer membrane proteins of branhamella catarrhalis. | branhamella catarrhalis has emerged as an important human pathogen in the past several years. therefore, studies of the outer membrane have been undertaken in order to identify virulence factors and begin to understand the immune response to infection. | 1990 | 1692665 |
| on the proteolytic activity of contact lenses and bacteria. | contact lens wear (clw) has been shown to cause an elevation in tear fluid (tf) plasmin levels. this study investigated whether the proteolytic activity assayed by a caseinolytic technique was also bound by cls and whether certain bacterial species contribute to the production of plasmin. cls worn by patients with corneal disease showed proteolytic activity in five out of nine cases when examined on casein agar. histological and electron microscopic examination of the lenses revealed bacterial a ... | 1990 | 1699389 |
| fulminant branhamella catarrhalis tracheitis. | branhamella catarrhalis, a well known commensal of the normal respiratory flora, is being increasingly implicated as an aetiological agent in various acute respiratory and non-respiratory infections. b. catarrhalis has demonstrated a particular predilection for turning pathogenic in the immunocompromised host. bacterial tracheitis, presenting as an acute airway obstruction, is commonly caused by staphylococcus aureus and haemophilus influenzae. the unusual occurrence of a fulminant b. catarrhali ... | 1990 | 1699488 |
| branhamella catarrhalis: antigenic determinants and the development of the igg subclass response in childhood. | a recently developed whole cell elisa was used to investigate the development of igg subclass antibodies to branhamella catarrhalis in childhood. in addition, sds-page and immunoblotting were used to study the interaction between the outer membrane proteins (omps) of b. catarrhalis and igg subclass antibodies. specific igg3 antibodies were undetectable or present only in low amounts in children less than 4 years old but were an important constituent of the response of older children. omps prepar ... | 1990 | 1700025 |
| interpretation of gram-stained sputa containing moraxella (branhamella) catarrhalis. | sputum specimens culture positive for moraxella (branhamella) catarrhalis were gram stained with three decolorizer solutions (slow, 95% ethyl alcohol; intermediate, 1:1 ratio of 95% ethyl alcohol and acetone; and fast, acetone alone) for 5, 10, 20, and 30 s. optimal results were obtained with acetone alone after 10 s or with a 1:1 mixture of acetone and ethanol after 20 s. inadequate decolorization of m. catarrhalis in sputa is likely if the decolorization solution and exposure time are not opti ... | 1990 | 1701446 |
| [tuberculosis sequelae: secondary bacterial infections]. | bacterial infections is one of the most important complications in the patients with pulmonary tuberculosis. we reported the causative microorganisms in these cases with special reference to various clinical features and presented the recommended treatment and prophylaxis against respiratory bacterial infections in the patients with pulmonary tuberculosis sequelae. in 1988 and 1989, 63 patients with tuberculosis sequela were demonstrated to have been infected with respiratory pathogenic bacteria ... | 1990 | 2077264 |
| in-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. | the in-vitro activity of sparfloxacin (at-4140), a new difluorinated quinolone, was compared with those of ciprofloxacin, temafloxacin and selected members of other groups of antimicrobial agents, against 651 recent distinct clinical isolates and strains with known mechanisms of resistance. three strains of chlamydia trachomatis were also studied. the mics for 90% of the enterobacteriaceae were between 0.06 and 1 mg/l; for pseudomonas aeruginosa the mic90 was 2 mg/l. sparfloxacin was 16-fold mor ... | 1990 | 2079449 |
| [anaerobic bacteria detected in inflammatory conditions of the respiratory tract]. | in this study a participation of anaerobic bacteria in respiratory tract diseases is presented. bronchial washings collected by ++fibrobronchoscope constituted material for the study. immediately after collection the material was plated onto two media for aerobic bacteria (hemomedium) and anaerobic bacteria (anaeromedium). then, the samples were centrifuged and a sediment was plated on solid media suitable for aerobic and anaerobic bacteria. bacterial anaerobic isolates were identified by using ... | 1990 | 2084446 |
| [susceptibilities of clinical bacterial isolates to antimicrobial agents. a study mainly focused on imipenem. research group for testing imipenem susceptibility on clinical isolates]. | we investigated susceptibilities of clinical bacterial isolates to imipenem (ipm) and other antimicrobial agents at 459 hospital laboratories throughout japan from september to december of 1988. in this study, identification and susceptibility testing were performed at each hospital laboratory and the tests were carried out according to the 1-dilution or 3-dilution disc technique in which susceptibilities are classified into 4 grades: , ++, + and -. ipm had significantly high activity against st ... | 1990 | 2086814 |
| evaluation of bacto tb hydrolysis reagent (tween 80) for the identification of branhamella catarrhalis. | an investigation of the hydrolysis of tween 80 reagent by branhamella catarrhalis and related organisms (neisseria and moraxella species) revealed that only b. catarrhalis gave a positive result. a total of 226 strains, including reference organisms and clinical isolates, were studied. b. catarrhalis changed the color of the reagent from amber to pink-red after overnight incubation. we recommend this simple and cost-effective test as an alternative procedure to dnase testing or tributyrin hydrol ... | 1990 | 2105335 |
| cefaclor treatment of upper and lower respiratory tract infections caused by moraxella catarrhalis. | a retrospective analysis of data from 18 clinical studies was performed to examine the effectiveness and safety of cefaclor in the treatment of upper and lower respiratory tract infections caused by moraxella catarrhalis (previously called branhamella catarrhalis). eighty-six percent of 56 evaluable patients had improvement in their symptoms of infections following therapy with cefaclor. there were no serious or life-threatening adverse drug experiences reported by any patient. cefaclor appears ... | 1990 | 2105479 |
| [infections caused by branhamella catarrhalis]. | branhamella catarrhalis, formerly neisseria catarrhalis, is a common bacteriological finding in the upper respiratory tract in infancy, and it ranks third on the list of bacterial causes of otitis media and sinusitis. in adults branhamella catarrhalis may cause acute exacerbations of bronchitis and pneumonia, especially in patients with chronic lung disease. branhamella catarrhalis is being recognized more frequently as a nosocomial pathogen and it may cause septicaemia in immunocompromised pati ... | 1990 | 2106743 |
| antibodies against streptococcus pneumoniae, haemophilus influenzae and branhamella catarrhalis in middle ear effusion during early phase of acute otitis media. | serum type (igg, igm and iga-class) and secretory type antibodies specific to streptococcus pneumoniae (pn), haemophilus influenzae (hi) and branhamella catarrhalis (br) were measured by enzyme-linked immunosorbent assay (elisa) in 46 serum and 114 middle ear effusion (mee) samples from 85 children with acute otitis media (aom). the samples were obtained within 12 h from the onset of the ear symptoms. serum (but not secretory) type antibodies to the infecting pn serotype were found in 24% of the ... | 1990 | 2106760 |
| branhamella catarrhalis pneumonia with bacteremia in a pediatric patient with smoke inhalation. | branhamella catarrhalis, a common inhabitant of the upper respiratory tract, has been identified recently as a cause of lower airway infection. in this report we present a case of b. catarrhalis pneumonia and bacteremia in a child with smoke inhalation as the first description of invasive disease involving this organism in a traumatized airway. in addition, other pediatric cases of b. catarrhalis bacteremia are reviewed, suggesting immunocompromise as a risk factor. | 1990 | 2107181 |
| serological typing of branhamella catarrhalis strains on the basis of lipopolysaccharide antigens. | a total of 302 strains of branhamella catarrhalis from different parts of the world were serologically typed according to their lipopolysaccharide (lps) antigenicity. for this purpose, an inhibition enzyme-linked immunosorbent assay was developed using the following reagents: antisera raised against whole bacterial suspensions for a panel of 16 serotype strains and lps prepared from these strains by phenol extraction. antisera were absorbed with whole bacterial suspensions of the b. catarrhalis ... | 1990 | 2107197 |
| [a review of four cases of branhamella catarrhalis bacteremia in children]. | branhamella catarrhalis was recovered from one blood culture each from three infants and one neonate admitted to the trousseau hospital (paris) between 1986 and 1988. clinical features included fever in every case, otitis in three cases, pneumonia in two cases, diarrhea in one case, and enterocolitis in one case. all the strains were beta-lactamase producers. outcome was favorable in every case. the antimicrobial agent used was erythromycin in one case, amoxicillin in one case, and a third gener ... | 1990 | 2107783 |
| treatment of branhamella catarrhalis infections. | 1990 | 2108111 | |
| an enzyme-linked immunosorbent assay for the determination of human igg subclass antibodies directed against branhamella catarrhalis. | an elisa procedure to determine the distribution of human igg subclass antibodies directed against the gram-negative bacterium branhamella catarrhalis has been developed using commercially available monoclonal anti-igg subclass antibodies. using whole bacteria as coating antigen the specificity of the assay was determined and showed minimal cross-reactivity with a range of other bacteria. estimations of igg1, igg2, igg3, igg4 and total igg antibodies directed against this antigen were performed. ... | 1990 | 2109016 |
| in-vitro activity of ampicillin/sulbactam and other antibiotics against clinical isolates of haemophilus sp. and branhamella catarrhalis. | the ampicillin/sulbactam combination is one of several such drug combinations of a beta-lactam and suicide inhibitor having a wide spectrum of activity. these characteristics induced us to evaluate the in vitro activity of this combination towards 54 strains of haemophilus sp. (38 beta-lactamase producers) and 20 strains of branhamella catarrhalis (16 beta-lactamase producers). all strains were isolated from sputum, sinusal aspiration and tympanocentesis. in the case of haemophilus sp beta-lacta ... | 1990 | 2110245 |
| branhamella catarrhalis: a microbiologic and clinical update. proceedings of a symposium. houston, texas, september 15, 1989. | 1990 | 2111086 | |
| spectrum of disease due to branhamella catarrhalis in children with particular reference to acute otitis media. | for many years branhamella catarrhalis was regarded as a non-pathogenic inhabitant of the respiratory tract. this article outlines the spectrum of b. catarrhalis disease in childhood and the extent of the evidence for a pathogenic role of the organism. b. catarrhalis is a rare etiologic agent in septicemia, meningitis, and other systemic illness in both apparently normal and immunocompromised infants and children. it is an unusual cause of ophthalmia neonatorum, but can be confused with neisseri ... | 1990 | 2111087 |
| a descriptive study of 42 cases of branhamella catarrhalis pneumonia. | we studied the clinical and laboratory findings of patients with pneumonia due to moraxella (branhamella) catarrhalis to better characterize the types of patients who develop this pneumonia, the clinical features of the illness, and the type of and response to drug therapy, as well as the immediate and long-term survival of these patients. | 1990 | 2111088 |
| antibody response to p-protein in patients with branhamella catarrhalis infections. | branhamella catarrhalis is now recognized as an important cause of lower respiratory tract infections, especially in the elderly. in most instances, pathogenicity is presumed by recovery of the organism in a sputum culture, a method that is less than conclusive. in order to better diagnose b. catarrhalis infections, an enzyme-linked immunoassay has been developed using p-protein as antigen to measure antibodies to b. catarrhalis. in 17 elderly patients with b. catarrhalis pneumonia and 12 with t ... | 1990 | 2111089 |
| a comparison of serum bactericidal activity and phenotypic characteristics of bacteremic, pneumonia-causing strains, and colonizing strains of branhamella catarrhalis. | four blood isolates, 12 pneumonia isolates, and seven colonizing isolates of branhamella catarrhalis were compared with respect to their ability to grow in normal human serum and in convalescent serum of a patient with b. catarrhalis bacteremia. disease-causing isolates showed seven of 16 serum-resistant strains (43 percent) compared with one of seven (13 percent) colonizing strains. bacteremic strains were not more serum-resistant than pneumonia-causing strains. trypsin zones of inhibition were ... | 1990 | 2111090 |
| branhamella catarrhalis: phenotypic characteristics. | purpose: this review provides a comprehensive description and discussion of recognized phenotypic characteristics of branhamella catarrhalis. an emphasis is placed on attributes of this organism that are relevant to its recovery and identification in the clinical microbiology laboratory. in addition, characteristics useful in determining strain identity for use in epidemiologic investigations are addressed. finally, factors are discussed that may account for the infection-causing potential of b. ... | 1990 | 2111091 |
| antibiotic susceptibilities and drug resistance in moraxella (branhamella) catarrhalis. | to summarize current knowledge of drug susceptibility and mechanisms of drug resistance in moraxella (branhamella) catarrhalis. | 1990 | 2111092 |
| respiratory infections caused by branhamella catarrhalis. selected epidemiologic features. | this work reviewed existing literature pertaining to the epidemiologic aspects of respiratory tract infections caused by branhamella catarrhalis, examined certain epidemiologic features of b. catarrhalis infections occurring at this facility, and identified relevant areas in need of further study. | 1990 | 2111094 |
| the changing pattern of antibiotic resistance of neisseria gonorrhoeae. | 1990 | 2111274 | |
| the changing pattern of antibiotic resistance of neisseria gonorrhoeae. | 1990 | 2111274 | |
| on branhamella catarrhalis pneumonia. | 1990 | 2112238 | |
| moraxella (branhamella) catarrhalis bacteremia. a case report and literature review. | moraxella catarrhalis is increasingly recognized as a cause of pulmonary and upper airway disease, but bacteremia remains unusual. we treated a 71-year-old man who died of rapidly progressive bacteremic m catarrhalis bronchopneumonia. this case, and a review of the 27 previously reported m catarrhalis bacteremias in the literature, demonstrated that m catarrhalis can be a virulent organism capable of causing serious infection and death in both immunocompetent and compromised hosts. | 1990 | 2112907 |
| bacterial isolates and cigarette smoking in patients with chronic bronchitis: results from an italian multicenter survey. | patients who were cigarette smokers suffering exacerbations of chronic bronchitis were examined in eight outpatient clinics in five regions of italy, three from the south (campania, 82 patients; sicily, 82 patients; and puglia, 29 patients) and two from north (lombardy, 33 patients; and liguria, 50 patients). haemophilus influenzae was the most frequently isolated bacterium in the patients' sputum (in 30% of the total group), followed by streptococcus pneumoniae (in 20%), staphylococcus aureus ( ... | 1990 | 2112984 |
| comparative study of cefuroxime axetil suspension and amoxycillin syrup in the treatment of acute otitis media in general practice. | in a multicentre general practice study, 660 children aged between 3 months and 12 years with otitis media were randomized to receive a 10-day course of cefuroxime axetil suspension or amoxycillin syrup. children under 2 years of age were given 125 mg cefuroxime axetil twice daily after food or 125 mg amoxycillin three times daily; older children received 250 mg cefuroxime axetil twice daily or 250 mg amoxycillin three times daily. the overall cure or improvement rate was 94.3% for those treated ... | 1990 | 2113874 |
| [activity of cefapirin against bacterial strains isolated from acute otitis media in children]. | the antibacterial activity of cefapirin was tested against 210 strains isolated from the auricular exudate of childrens' acute otitis media. for 112 strains of haemophilus studied (20% secreted a beta-lactamase), the mic 50 and 90 of cefapirin were 2 and 4 mg/l respectively. ten strains of branhamella catarrhalis were tested (9 secreted a beta-lactamase) and the mic ranged from 0.25 to 4 mg/l. against streptococcus pneumoniae, cefapirin has an extremely high activity with mic 50 and 90 less than ... | 1990 | 2114604 |
| quantification of nasopharyngeal bacteria for diagnosis of respiratory tract infection in children. | agreement between clinical signs of bacterial respiratory tract infections and quantities of respiratory tract pathogens in nasopharynx was studied in 77 children, aged 6-13 years. specimens were obtained from 27 clinically bacterial and 51 clinically non-bacterial respiratory tract infections, and in 124 instances from healthy children. viable counts of streptococcus pneumoniae, haemophilus influenzae, branhamella catarrhalis, and beta-haemolytic streptococci were made from swab specimens suspe ... | 1990 | 2115205 |
| rapid identification of branhamella catarrhalis. a comparison of five rapid methods. | five methods for the rapid identification and differentiation of branhamella catarrhalis from other neisseria species in 86 respiratory specimens were compared. these tests included the 4-methylumbelliferyl butyrate (mub), api quadferm, b.cat.confirm, gonochek ii, and the tributyrin disc. all five tests reliably and accurately identified 31 b. catarrhalis isolates. however, the mub test was the least expensive, least labor intensive, and did not require overnight purity plates for performance. t ... | 1990 | 2116950 |
| randomized comparative study of cefixime versus cephalexin in acute bacterial exacerbations of chronic bronchitis. | patients with purulent exacerbation of chronic bronchitis were randomized to receive either a single 400-mg daily dose of cefixime or 250 mg of cephalexin, orally, four times a day. patients were males with a mean age of 63 years. of the 86 patients, 71 (82%) had bronchitis caused by a single organism (29 by haemophilus influenzae, 27 by branhamella catarrhalis, 9 by gram-negative enteric organisms, 6 by streptococcus pneumoniae), while more than one pathogen was implicated in 15 patients (18%). ... | 1990 | 2118322 |
| effect of ampicillin, cefmetazole and minocycline on the adherence of branhamella catarrhalis to pharyngeal epithelial cells. | using pharyngeal epithelial cells from a healthy adult and eight strains of branhamella catarrhalis (b. catarrhalis) isolated from eight patients with respiratory infection the effect of subminimal inhibitory concentrations of cefmetazole, ampicillin and minocycline on adherence was examined. cefmetazole-treated bacterial attachment (44 +/- 28; mean +/- s.d.) decreased significantly (p less than 0.05) compared to the control (84 +/- 27). statistically no significant difference in adherence was f ... | 1990 | 2118692 |